{"id":"comparator-mk0517","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL3983509","moleculeType":"Small molecule","molecularWeight":"434.92"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MK0517 crosses the blood-brain barrier and competitively binds to NK1 receptors, preventing substance P from activating these receptors. Substance P is a neuropeptide involved in pain transmission and emetic signaling, so NK1 antagonism is hypothesized to reduce chemotherapy-induced nausea and vomiting (CINV) and potentially treat other conditions involving pain or mood dysregulation.","oneSentence":"MK0517 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:03.870Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV)"}]},"trialDetails":[{"nctId":"NCT01697579","phase":"PHASE2","title":"Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-13","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":240},{"nctId":"NCT01362530","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09-13","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":307},{"nctId":"NCT01732458","phase":"PHASE2","title":"A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-02-12","conditions":"Post-operative Nausea, Post-operative Vomiting","enrollment":229},{"nctId":"NCT00818259","phase":"PHASE1","title":"A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02-05","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":92},{"nctId":"NCT01594749","phase":"PHASE3","title":"Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-24","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":1015},{"nctId":"NCT00952341","phase":"PHASE3","title":"Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-08-25","conditions":"Chemotherapy-induced Nausea and Vomiting (CINV)","enrollment":421},{"nctId":"NCT00337727","phase":"PHASE3","title":"Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01-01","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":848},{"nctId":"NCT00090246","phase":"PHASE3","title":"2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-05-13","conditions":"Postoperative Nausea and Vomiting","enrollment":922},{"nctId":"NCT00034944","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-01-24","conditions":"Major Depressive Disorder","enrollment":495},{"nctId":"NCT00048607","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-07-30","conditions":"Major Depressive Disorder","enrollment":600},{"nctId":"NCT00035048","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-11-21","conditions":"Major Depressive Disorder","enrollment":540},{"nctId":"NCT00090155","phase":"PHASE3","title":"2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-09-26","conditions":"Postoperative Nausea and Vomiting","enrollment":805},{"nctId":"NCT00042029","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-06-18","conditions":"Major Depressive Disorder","enrollment":324},{"nctId":"NCT00092183","phase":"PHASE4","title":"An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-10-10","conditions":"Nausea, Vomiting, Breast Neoplasms","enrollment":866},{"nctId":"NCT00048594","phase":"PHASE3","title":"Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-01-03","conditions":"Major Depressive Disorder","enrollment":800},{"nctId":"NCT00034983","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-10-29","conditions":"Major Depressive Disorder","enrollment":900},{"nctId":"NCT00090207","phase":"PHASE4","title":"Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-01-13","conditions":"Nausea, Vomiting","enrollment":477},{"nctId":"NCT00035009","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-09-20","conditions":"Major Depressive Disorder","enrollment":468},{"nctId":"NCT00035295","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-11-08","conditions":"Major Depressive Disorder","enrollment":584},{"nctId":"NCT00619359","phase":"PHASE3","title":"Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":2322},{"nctId":"NCT00231777","phase":"PHASE3","title":"A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07","conditions":"Post-Operative Nausea and Vomiting","enrollment":216},{"nctId":"NCT00035282","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-09","conditions":"Major Depressive Disorder","enrollment":450},{"nctId":"NCT00945321","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":42},{"nctId":"NCT00835965","phase":"NA","title":"Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries","status":"UNKNOWN","sponsor":"Main Line Health","startDate":"2009-02","conditions":"Nausea, Vomiting","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Comparator: MK0517","genericName":"Comparator: MK0517","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MK0517 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system. Used for Chemotherapy-induced nausea and vomiting (CINV).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}